Neoadjuvant Immunotherapy Achieves 100% No-Recurrence in MSI-H Colorectal Cancer Trial
TL;DR Summary
A small NEOPRISM-CRC trial at University College London treated stage II/III colorectal cancers with MSI-H/MMR-deficient tumors using pembrolizumab before surgery. After nearly three years of follow-up, no patient experienced cancer recurrence, suggesting neoadjuvant immunotherapy could spare or reduce chemotherapy for this 10–15% subset of bowel cancers, though larger studies are needed to confirm efficacy and applicability.
- New Immunotherapy Trial Shows 100% Success Rate Against One Type of Bowel Cancer ZME Science
- Bowel cancer immunotherapy clinical trial follow-up shows zero relapses Medical Xpress
- Presurgery Pembrolizumab May Be the Future for Some Operable CRCs Inside Precision Medicine
- Breakthrough drug trial to eradicate bowel cancers surging in young adults The Mirror
- New bowel cancer treatment ‘highly effective’, research suggests | ITV News ITVX
Reading Insights
Total Reads
0
Unique Readers
23
Time Saved
25 min
vs 25 min read
Condensed
99%
4,977 → 56 words
Want the full story? Read the original article
Read on ZME Science